BidaskClub Upgrades Nabriva Therapeutics (NBRV) to Buy

BidaskClub upgraded shares of Nabriva Therapeutics (NASDAQ:NBRV) from a hold rating to a buy rating in a research note published on Tuesday morning, BidAskClub reports.

Several other research analysts have also recently weighed in on the company. Needham & Company LLC reissued a buy rating and issued a $10.00 price objective (down previously from $15.00) on shares of Nabriva Therapeutics in a research report on Wednesday, May 1st. Northland Securities reaffirmed a buy rating and set a $12.50 price target on shares of Nabriva Therapeutics in a research report on Tuesday, March 12th. HC Wainwright reaffirmed a buy rating and set a $9.00 price target on shares of Nabriva Therapeutics in a research report on Monday, January 28th. Zacks Investment Research raised Nabriva Therapeutics from a hold rating to a buy rating and set a $2.25 price target on the stock in a research report on Tuesday, February 5th. Finally, Gabelli cut Nabriva Therapeutics from a buy rating to a sell rating and set a $2.56 price target on the stock. in a research report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $8.25.

NBRV stock traded down $0.11 during midday trading on Tuesday, hitting $2.60. The company’s stock had a trading volume of 9,417 shares, compared to its average volume of 1,800,473. The company has a current ratio of 5.55, a quick ratio of 6.11 and a debt-to-equity ratio of 0.40. Nabriva Therapeutics has a 1 year low of $1.12 and a 1 year high of $6.05. The stock has a market cap of $1.89 billion, a P/E ratio of -1.59 and a beta of 2.42.

Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. Nabriva Therapeutics had a negative return on equity of 119.75% and a negative net margin of 3,194.72%. The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $0.56 million. As a group, analysts forecast that Nabriva Therapeutics will post -1.15 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC lifted its position in shares of Nabriva Therapeutics by 77.0% during the 1st quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock valued at $7,958,000 after buying an additional 1,418,800 shares during the last quarter. Aisling Capital Management LP purchased a new position in shares of Nabriva Therapeutics during the 4th quarter valued at $2,642,000. BlackRock Inc. lifted its position in shares of Nabriva Therapeutics by 99.5% during the 3rd quarter. BlackRock Inc. now owns 936,624 shares of the biotechnology company’s stock valued at $2,529,000 after buying an additional 467,119 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Nabriva Therapeutics by 61.4% during the 1st quarter. Renaissance Technologies LLC now owns 855,765 shares of the biotechnology company’s stock valued at $2,088,000 after buying an additional 325,600 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Nabriva Therapeutics by 26.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 759,245 shares of the biotechnology company’s stock valued at $1,853,000 after buying an additional 158,852 shares during the last quarter. 4.61% of the stock is currently owned by hedge funds and other institutional investors.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Read More: What are the benefits of buying treasury bonds?

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.